Resources Repository
-
ArticlePublication 2021Rational Policymaking during a Pandemic
Policymaking during a pandemic can be extremely challenging. As COVID-19 is a new disease and …
Policymaking during a pandemic can be extremely challenging. As COVID-19 is a new disease and its global impacts are unprecedented, decisions are taken in a highly uncertain, complex, and rapidly changing environment. In such a context, in which human lives and the economy are at stake, the authors argue that using ideas and constructs from modern decision theory, even informally, will make policymaking a more responsible and transparent process.
Decision Theory | Policy/Regulation | Priority Setting/Ethics | Infectious Diseases | Government/Law | Health/Medicine | Science/Technology | Global -
ArticlePublication 2021Distributional Health and Financial Consequences of Increased Cigarette Tax in Iran: An ECEA
This study examines the potential impact of a tax-induced cigarette price increase on financial and …
This study examines the potential impact of a tax-induced cigarette price increase on financial and health outcomes across different socioeconomic groups in Iran. Using pooled cross-sectional data from Household Income and Expenditure Surveys (2002–2017) and population data from Iran in 2019, an extended cost-effectiveness analysis (ECEA) methodology is employed to model the effects of a hypothetical increase in cigarette tax. The analysis evaluates health benefits, health expenditures averted, additional tax revenues generated, changes in household…
Policy/Regulation | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Middle East & North Africa -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Policy/Regulation | Probability/Bayes | Test Performance | Technology Assessment | Infectious Diseases | Health Systems | Government/Law | Health/Medicine | Global | North America -
Resource PackPublication, Teaching Resource 2020Resource Pack: SSB Excise Tax Briefs (CHOICES)
Rising rates of obesity represent one of the greatest public health threats facing the United …
Rising rates of obesity represent one of the greatest public health threats facing the United States. Obesity has been linked to excess consumption of sugary drinks. Federal, state, and local governments have considered implementing excise taxes on sugary drinks to reduce consumption, reduce obesity, and provide a new source of government revenue. This resource pack includes a series of briefs describing analyses conducted by the Childhood Obesity Intervention Cost-Effectiveness Study (CHOICES), evaluating the health and economic impact…
Policy/Regulation | Health Outcomes | Microsimulation | Cost-Effectiveness Analysis | Child/Nutrition | Chronic Disease/Risk | Social Determinants | Business/Industry | Economics/Finance | Government/Law | Health/Medicine | North America | College | Graduate | Doctoral | Professional | Decision Making/Leadership | Policy Translation | Quantitative Literacy -
ArticlePublication 2020Premature Deaths, Statistical Lives, and Years of Life
This article clarifies some misconceptions about mortality risk and economic valuation. The mortality effects of …
This article clarifies some misconceptions about mortality risk and economic valuation. The mortality effects of exposure to environmental hazards such as air pollution are often described by the estimated number of “premature deaths” and the economic value of an exposure reduction as the number of “statistical lives saved” multiplied by the “value per statistical life.” These terms can be misleading because the number of deaths advanced by exposure cannot be determined from mortality data; it…
Policy/Regulation | Preferences/Values | Health Outcomes | Benefit-Cost Analysis | Environmental Health | College | Graduate | Critical Thinking/Analysis -
ArticlePublication 2018Comparing Cost-per-QALYs Gained to Cost-per-DALYs Averted
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, …
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, the Tufts Medical Center CEA Registry (cost-per-QALY gained studies), and the Global Cost-Effectiveness Analysis (GHCEA) Registry (cost-per-DALY averted studies). Study characteristics that were analyzed included intervention type, sponsor, country, primary disease, and number of CEAs versus disease burden estimates for major conditions. The authors report that cost-per-QALY studies were most often about pharmaceuticals or interventions in high-income countries while cost-per-DALY…
Policy/Regulation | Evidence Synthesis | Cost-Effectiveness Analysis | Health/Medicine | Global -
ReportPublication 2019Top 10 Health Economics and Outcomes Research Trends
As governments and other payers struggle with provision of the best possible health outcomes at …
As governments and other payers struggle with provision of the best possible health outcomes at affordable costs, the field of health economics and outcomes research (HEOR) has experienced rapid growth. The International Society for Pharmacoeconomics Outcomes Research (ISPOR) produced the ISPOR 2019 Top 10 HEOR Trends which serves to outline the top 10 that the Society members identified that will be the most impactful during 2019. Development of this report included a comprehensive review and…
Policy/Regulation | Health Outcomes | Social Determinants | Health Systems | Global Governance | Health/Medicine | Science/Technology | Global -
OrganizationWeb Portal 2024Society for Benefit-Cost Analysis
The Society for Benefit-Cost Analysis (SBCA), founded in 2007, works to improve the theory and …
The Society for Benefit-Cost Analysis (SBCA), founded in 2007, works to improve the theory and practice of benefit-cost analysis and support evidence-based policy decisions. It addresses policy areas including public health, transportation, criminal justice, education, energy, environmental quality, homeland security, and poverty. Members include scholars and practitioners from around the world, who work in government, academia, nonprofits and private industry. Its members represent numerous disciplines such as economics, law, engineering, public policy, decision science, and…
Policy/Regulation | Preferences/Values | Priority Setting/Ethics | Costing Methods | Benefit-Cost Analysis | Social Determinants | Environmental Health | Business/Industry | Climate/Environment | Economics/Finance | Energy/Engineering | Education/Labor | Food/Agriculture | Government/Law | Health/Medicine | Military/Defense | Science/Technology | Global | Critical Thinking/Analysis -
ReportPublication 2010Priorities for the National Vaccine Plan
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine …
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine and public health, from research and development of new vaccines to financing and reimbursement of immunization services. The current climate, socially, economically and politically, presents challenges and opportunities to the U.S. to strengthen the existing systems of developing, manufacturing, regulating, distributing, funding, and administering safe and effective vaccines for all people. The authors present recommendations for priority actions intended to…
Policy/Regulation | Evidence Synthesis | Technology Assessment | Infectious Diseases | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | Science/Technology | North America